IDH2 and glioblastoma: In the “Selected GBMs” group, a Kaplan-Meier survival analysis was performed on patients with a histopathological diagnosis of glioblastoma, regardless of tumor biology (IDH status or MGMT promoter status), and regardless of subsequent chemoradiation, by extent of resection using the four tiers described above.